Navigating Your Treatment Path

Treating acromegaly is not a single event, but a structured process of matching the right therapy to your specific tumor, hormone levels, and personal health profile. Current international guidelines from the Endocrine Society and the Acromegaly Consensus Group provide a framework of options designed to first address the tumor mass and then normalize your hormones ^[1][2].

The First Step: Surgery

For a removable tumor, transsphenoidal surgery is generally the first-line treatment ^[3][4]. In this procedure, a neurosurgeon reaches the pituitary gland through the nose.

• Goal: To remove as much of the tumor as possible, relieve pressure on nearby structures like the optic nerves, and aim for postoperative biochemical control ^[4].
• Success Rates: The effectiveness of surgery depends on the tumor’s size, invasion into nearby areas (like the cavernous sinus), and the surgeon’s expertise ^[5]. It is important to know that biochemical control is assessed at the appropriate follow-up interval (usually weeks to months later), and symptom improvement and hormone normalization occur on different timelines.

Note that primary medical therapy can be appropriate instead of surgery for selected invasive or unresectable tumors, or when there is substantial surgical risk ^[4].

The Medical Decision Tree

If surgery does not fully normalize your IGF-1 levels, or if surgery is not an option for you, medical therapy becomes the next step.

1. First-Line Medical Therapy: Somatostatin Receptor Ligands (SRLs)

The standard first medications are often octreotide LAR and lanreotide ^[6]. These are typically monthly injections that mimic a natural hormone in your body to “turn off” growth hormone production.

• Efficacy: They normalize IGF-1 in roughly 30% to 50% of patients and can shrink the tumor in about 60% of cases ^[7][8].
• Harms/Side Effects: Common issues include gastrointestinal symptoms (diarrhea, nausea, abdominal pain) and the development of biliary sludge or gallstones ^[9][10]. What to report: Tell your doctor immediately if you experience severe abdominal pain, fever, or jaundice (yellowing of the skin/eyes). Ultrasound monitoring for gallstones is individualized based on baseline risks and symptoms.

2. Second-Line and Combination Options

If first-generation SRLs are not enough, your doctor may move to more specialized medications:

• Pegvisomant (GH-Receptor Antagonist): This drug blocks growth hormone from working at the site of the liver ^[11]. It is highly effective at normalizing IGF-1. However, because it does not usually shrink the adenoma, residual tumor requires baseline and periodic MRI imaging surveillance ^[12].
  • Monitoring: It requires regular liver-function tests because it can cause reversible transaminase elevation (liver stress). It can also cause skin changes at the injection site called lipohypertrophy ^[11][13]. What to report: Concerning liver symptoms (fatigue, dark urine, jaundice) or injection-site changes.
• Pasireotide LAR: A more potent SRL that targets multiple receptors. It is often effective when others fail ^[14].
  • Serious Risk: Its primary drawback is a high risk of new or worsening hyperglycemia (high blood sugar) and diabetes. Frequent glucose monitoring is mandatory ^[15][16]. What to report: Marked hyperglycemia symptoms such as extreme thirst, frequent urination, or blurred vision.
• Cabergoline: An oral pill sometimes used for very mild cases or as an “add-on” to injections ^[17].

Radiation: An Individualized Option

Radiation therapy (either stereotactic radiosurgery or fractionated radiotherapy) may be selected for persistent, aggressive, or medication-resistant disease ^[5][4].

While radiation can be very effective at stopping tumor growth over time, it carries a high risk of hypopituitarism—the permanent loss of other essential pituitary hormones ^[18]. This effect is “delayed,” meaning it can take 5, 10, or even 20 years to fully develop ^[19]. Patients who undergo radiation must have their hormone levels tested at least once a year for the rest of their lives ^[20].